Observational studyDiabetes/metabolism research and reviews2025
Risk of Ischaemic and Non-Ischaemic Heart Failure in People With Type 2 Diabetes: Observational Study in 1.6 Million People in England.
Observational study in Diabetes/metabolism research and reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk of Ischaemic and Non-Ischaemic Heart Failure in People With Type 2 Diabetes: Observational Study in 1.6 Million People in England.Diabetes/metabolism research and reviews · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aims/hypothesisRecent evidence shows decreasing trends for ischaemic heart disease over time in the general population as well as in those with type 2 diabetes. As type 2 diabetes has been associated with an increased risk of both ischaemic and non-ischaemic heart failure, a greater proportion of people with type 2 diabetes could now be presenting with non-ischaemic heart failure phenotypes. We aimed to investigate the risk of incident ischaemic and non-ischaemic heart failure in people with type 2 diabetes.
methodsWe used the Clinical Practice Research Datalink primary care data, linked to hospital and mortality records, to identify newly diagnosed adults with type 2 diabetes between 2000 and 2021, who were matched to up to four people without diabetes by sex, year of birth, and general practice. Ischaemic heart failure was defined as incident heart failure at or following an ischaemic heart disease event; non-ischaemic HF was defined as incident heart failure in the absence of prevalent ischaemic heart disease. We used Poisson and Royston-Parmar models to estimate, respectively, the incidence rates and the hazard ratios (adjusted for sociodemographic and clinical confounders) for ischaemic and non-ischaemic heart failure, comparing people with type 2 diabetes to those without diabetes.
resultsIn a cohort of 1,621,090 people (mean age, 60.1 years; 52.8% women; 532,185 with type 2 diabetes), during a median follow-up of 5.8 (interquartile range: 2.6-10.3) years, a heart failure event occurred in 20,016 (3.8%) people with type 2 diabetes (ischaemic: 5046; non-ischaemic: 14,970) and in 29,835 (2.7%) without diabetes (7001 and 22,834, respectively). Age-standardised rates were higher for non-ischaemic (3.18 [95% CI: 3.09-3.27] vs. 2.08 [2.03-2.12] per 1000 person-years in men with type 2 diabetes vs. without diabetes; and 2.47 [2.39-2.54] vs. 1.57 [1.53-1.61], respectively, in women) than ischaemic (corresponding estimates: 1.57 [1.51-1.63] vs. 0.95 [0.92-0.98] and 0.80 [0.76-0.84] vs. 0.46 [0.44-0.48]) heart failure. Comparing people with type 2 diabetes versus those without diabetes, the hazard ratios were larger for ischaemic (adjusted hazard ratio: 1.36 [1.28-1.45] and 1.30 [1.20-1.42] in men and women, respectively) than non-ischaemic (1.12 [1.07-1.16] and 1.10 [1.06-1.14], respectively) heart failure. CONCLUSIONS/INTERPRETATIONS: The higher rates of non-ischaemic heart failure highlight the need for early prevention before ischaemic heart disease develops, regardless of type 2 diabetes. Meanwhile, the greater excess risk of ischaemic heart failure in those with type 2 diabetes suggests suboptimal post-ischaemic prevention in this group.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.